0 Ratings

ID

14798

Description

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor; ODM derived from: https://clinicaltrials.gov/show/NCT00754325

Link

https://clinicaltrials.gov/show/NCT00754325

Keywords

  1. 4/28/16 4/28/16 -
Uploaded on

April 28, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility Advanced Breast Cancer NCT00754325

    Eligibility Advanced Breast Cancer NCT00754325

    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    histologically confirmed hormone receptor positive (hr+) [(estrogen receptor (er+) and/or progesterone receptors(pgr+)] breast cancer according to immunohistochemistry (ihc)
    Description

    hormone receptor positive breast cancer

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1562029
    measureable or evaluable-only disease
    Description

    measureable disease

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1513041
    human epidermal growth factor receptor 2+ (her2+) or her2- breast cancer
    Description

    epidermal growth factor receptor breast cancer

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1960925
    males and females ≥18 years of age
    Description

    age

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    females are post menopausal or surgically sterile
    Description

    post menopausal or surgically sterile

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0021359
    UMLS CUI [2]
    C0232970
    recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant aromatase inhibitor (ai) treatment or (b) during ai treatment in advanced setting (metastatic therapy)
    Description

    recurrent or progressive advanced breast cancer

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0596224
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    pregnant or breast feeding
    Description

    pregnant or breast feeding

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0549206
    UMLS CUI [2]
    C0006147
    >1 chemotherapy regimen for advanced disease
    Description

    chemotherapy regimen

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0392920
    pleural or pericardial effusion
    Description

    pleural or pericardial effusion

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0032227
    UMLS CUI [2]
    C0031039
    serious cardiac condition
    Description

    cardiac condition

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0018799

    Similar models

    Eligibility Advanced Breast Cancer NCT00754325

    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    C1512693 (UMLS CUI)
    hormone receptor positive breast cancer
    Item
    histologically confirmed hormone receptor positive (hr+) [(estrogen receptor (er+) and/or progesterone receptors(pgr+)] breast cancer according to immunohistochemistry (ihc)
    boolean
    C1562029 (UMLS CUI [1])
    measureable disease
    Item
    measureable or evaluable-only disease
    boolean
    C1513041 (UMLS CUI [1])
    epidermal growth factor receptor breast cancer
    Item
    human epidermal growth factor receptor 2+ (her2+) or her2- breast cancer
    boolean
    C1960925 (UMLS CUI [1])
    age
    Item
    males and females ≥18 years of age
    boolean
    C0001779 (UMLS CUI [1])
    post menopausal or surgically sterile
    Item
    females are post menopausal or surgically sterile
    boolean
    C0021359 (UMLS CUI [1])
    C0232970 (UMLS CUI [2])
    recurrent or progressive advanced breast cancer
    Item
    recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant aromatase inhibitor (ai) treatment or (b) during ai treatment in advanced setting (metastatic therapy)
    boolean
    C0596224 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    pregnant or breast feeding
    Item
    pregnant or breast feeding
    boolean
    C0549206 (UMLS CUI [1])
    C0006147 (UMLS CUI [2])
    chemotherapy regimen
    Item
    >1 chemotherapy regimen for advanced disease
    boolean
    C0392920 (UMLS CUI [1])
    pleural or pericardial effusion
    Item
    pleural or pericardial effusion
    boolean
    C0032227 (UMLS CUI [1])
    C0031039 (UMLS CUI [2])
    cardiac condition
    Item
    serious cardiac condition
    boolean
    C0018799 (UMLS CUI [1])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial